ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Anti-citrullinated Protein Autoantibodies (ACPAs)"

  • Abstract Number: 0046 • ACR Convergence 2024

    Impaired Neutrophil Extracellular Trap (NET) Degradation in Rheumatoid Arthritis (RA) and Pre-clinical RA Is Mediated by Anti-NET Antibodies

    Jeba Atkia Maisha1, Alina Sememenko2, Jun Kim2, Mario Navarrete2, XIAOBO MENG1, Hani El-Gabalawy1 and Liam O'Neil1, 1University of Manitoba, Winnipeg, MB, Canada, 2University of Manitoba, Winnipeg, Canada

    Background/Purpose: Rheumatoid Arthritis (RA) begins after a prolonged preclinical phase which is marked by the development of RA antibodies, typically against citrullinated proteins (ACPA). The…
  • Abstract Number: 2247 • ACR Convergence 2024

    Pro-inflammatory Monocytes and CD11c Expression in ACPA Positive Individuals with Arthralgia and Their Associations with Subclinical Synovitis Preceding the Onset of Arthritis

    Klára Prajzlerová1, Olga Kryštufková2, Petra Hánová1, Nora Růžičková2, Hana Hulejová1, Jiří Vencovský2, Ladislav Šenolt2 and Mária Filková2, 1Institute of Rheumatology, Prague, Czech Republic, 2Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic

    Background/Purpose: Autoantibodies, e.g., against citrullinated proteins (ACPA), increase the risk of clinical arthritis and can be detected years before rheumatoid arthritis (RA) onset. EULAR's definition…
  • Abstract Number: 0056 • ACR Convergence 2024

    Association of Soluble Immune Checkpoint Proteins with the Risk of Developing RA in ACPA-positive At-risk Individuals

    Ryo Motoyama1, Shohei Nakamura1, Eisuke Inoue2, Hideto Takada3, Masayoshi Harigai4 and Yuko okamoto1, 1Tokyo Women's Medical University, Tokyo, Japan, 2Showa University, Tokyo, Japan, 3Tokyo Women's Medical University, Denver, CO, 4International University of Health and Welfare, Tokyo, Japan

    Background/Purpose: ACPA+ individuals without inflammatory arthritis are considered as being in an at-risk state of RA, although further factors are needed to identify individuals with…
  • Abstract Number: 2671 • ACR Convergence 2024

    Subcutaneous Abatacept vs Adalimumab Head-to-Head Comparison in Adults with Early, Dual Seropositive Rheumatoid Arthritis, Positive for the Shared Epitope HLA Class II Risk Alleles, and an Inadequate Response to Methotrexate: Results from a Phase 3 Trial

    Michael Weinblatt1, Paul Emery2, Vivian Bykerk3, Andrew Cope4, Gerd Burmester5, Yoshiya Tanaka6, Gustavo Citera7, Peter Nash8, Quentin Dornic9, Sheila Kelly10 and Michael Maldonado9, 1Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, 2University of Leeds, Leeds, United Kingdom, 3Hospital For Special Surgery, New York, NY, 4King's College London, London, United Kingdom, 5Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 6Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, 7Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 8Griffith University, Brisbane, Australia, 9Bristol Myers Squibb, Princeton, NJ, 10Bristol Myers Squibb, Doylestown, PA

    Background/Purpose: For patients (pts) early in their RA disease course, with a clinical profile characterized by inadequate response to MTX (MTX-IR), high titers of ACPA…
  • Abstract Number: 0057 • ACR Convergence 2024

    Flow Cytometry of Cells Within Induced Sputum from Individuals At-Risk for RA Reveals Relative Expansion of Small Macrophages

    Hideto Takada1, Brian Hattel2, Marie Feser3, LauraKay Moss2, Yuko Okamoto4, Mark Gillespie5, Adam Savage5, Troy Torgerson6, V. Michael Holers7, Kevin Deane8 and Kristen Demoruelle9, 1Tokyo Women's Medical University, Denver, CO, 2University of Colorado Anschutz Medical Campus, Denver, CO, 3Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 4Tokyo Women's Medical University Division of Rheumatology, Shinjyuku-ku, Tokyo, Japan, 5Allen Institute for Immunology, Seattle, WA, 6Allen Institute for Immunology, Enumclaw, WA, 7University of Colorado, Denver, CO, 8University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 9University of Colorado Anschutz Medical Campus, Golden, CO

    Background/Purpose: Serum elevations of ACPA in the absence of inflammatory arthritis is a well-established risk factor for the future development of clinical RA. The lung…
  • Abstract Number: 0064 • ACR Convergence 2024

    Anti-Citrullinated Protein Antibodies Arise During Affinity Maturation of Germline-Encoded Antibodies to Carbamylated Proteins in Rheumatoid Arthritis

    Marta Escarra-Senmarti1, Michael Chungyoun2, Dylan Ferris1, Jeffrey Gray2 and Felipe Andrade3, 1The Johns Hopkins University School of Medicine, Baltimore, MD, 2The Johns Hopkins Whiting School of Engineering, Baltimore, MD, 3The Johns Hopkins University School of Medicine, Timonium, MD

    Background/Purpose: The production of antibodies to modified self-antigens is a hallmark in rheumatoid arthritis (RA). Antibodies to citrullinated (ACPAs) and carbamylated proteins (CarP) are of…
  • Abstract Number: 0065 • ACR Convergence 2024

    Evidence of Membranolytic Targeting and Intracellular Citrullinationin Neutrophils Isolated from Patients with Rheumatoid Arthritis

    Neela Fatemeh Moadab1, Tal Gazitt2, Rayan Najjar1, Ethan Le1, J Lee Nelson3, Vijay Joshua4, Keith Elkon1, Caroline Grönwall4 and Tomas Mustelin1, 1University of Washington, Seattle, WA, 2Carmel Hospital, Haifa, Israel, 3University of Washington and Fred Hutchinson Cancer Center, Seattle, WA, 4Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Anti-citrullinated protein autoantibodies (ACPA) are diagnostic for rheumatoid arthritis (RA). The antigens recognized by these autoantibodies are produced by protein arginine deiminases (PADs), particularly…
  • Abstract Number: 0392 • ACR Convergence 2024

    Evaluation for the Presence of Antibodies to Malondialdehyde-Acetaldehyde Adduct in Juvenile Idiopathic Arthritis and Its Subtypes

    Geoffrey Thiele1, Panteha Hayati Rezvan2, Michal Cidon2, Carlos Hunter3, Michael Duryee3, Ted Mikuls3 and Geoffrey Thiele3, 1Children's Hospital of Los Angeles, Omaha, NE, 2Children's Hospital of Los Angeles, Los Angeles, CA, 3University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Studies of rheumatoid arthritis (RA) have shown that malondialdehyde-acetaldehyde (MAA) protein adducts and anti-MAA immune responses play a pathogenic role in disease progression. Expression of…
  • Abstract Number: 0458 • ACR Convergence 2024

    Long-Term Outcomes in Seronegative Rheumatoid Arthritis

    Bradly Kimbrough1, Cynthia Crowson2, Sara Achenbach3 and Elena Myasoedova2, 1Mayo Clinic Rochester, Rochester, MN, 2Mayo Clinic, Rochester, MN, 3Mayo Clinic, Rochester, Rochester, MN

    Background/Purpose: Seronegative rheumatoid arthritis (RA) is a heterogenous disease distinct from seropositive RA regarding genetic risk factors, pathobiology, and prognosis. Notably, recent studies have shown…
  • Abstract Number: 0464 • ACR Convergence 2024

    Increases in Paraoxonase-1 Activity over Time Associates with Reduced Risk of Incident Inflammatory Arthritis in an Anti-Citrullinated Protein Antibody-Positive Population

    Amir Razmjou1, Rong Guo2, David Elashoff3, Kevin Deane4, Jill Norris5, Marie Feser6, Jennifer Wang1, Ani Shahbazian2 and christina Charles-Schoeman7, 1UCLA, Los Angeles, CA, 2UCLA, Los Angeles, 3UCLA Department of Medicine Statistics Core, Los Angeles, 4University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 5Colorado School of Public Health, Denver, CO, 6Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 7UCLA Medical Center, Santa Monica, CA

    Background/Purpose: Rheumatoid arthritis (RA) has a well described pre-clinical state, with a continuum of genetic and environmental risk factors leading to the development of systemic…
  • Abstract Number: 0498 • ACR Convergence 2024

    ACPA Subtypes, RF Isotypes, and the Risk of Rheumatoid Arthritis-Associated Interstitial Lung Disease

    Jacob Welch1, Yangyuna Yang1, Joshua Baker2, Katherine Wysham3, Dana Ascherman4, Paul Monach5, Gail Kerr6, Andreas Reimold7, grant Cannon8, Gary Kunkel9, William Robinson10, Michael Duryee1, Geoffrey Thiele1, Ted Mikuls1 and Bryant England1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 4Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, 5VA Boston Healthcare System, Boston, MA, 6Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 7Dallas VA Medical Center, Dallas, TX, 8University of Utah and Salt Lake City VA, Salt Lake City, UT, 9University of Utah and George E Wahlen VAMC, Salt Lake City, UT, 10Stanford University, Palo Alto, CA

    Background/Purpose: Interstitial lung disease (ILD) is among the most significant extra-articular manifestations of rheumatoid arthritis (RA), clinically affecting 8-15% of RA patients, and accounting for…
  • Abstract Number: 0873 • ACR Convergence 2024

    Epigenetic Control of Pathogenic CD4 T Cell Polarization During Progression to Rheumatoid Arthritis (RA)

    Ziyuan He1, Pravina Venkatesan1, Adam Savage1, Marla Glass1, Lauren Okada2, Upaasana Krishnan2, Christy Bennett1, Nhung Tran2, Yudong He2, Samir Rachid Zaim1, Padmapriyadarshini Ravisankar2, Jessica Garber2, Palak Genge2, Kevin Lee2, Regina Mettey2, Cole Phalen2, Sugandhika Khosa2, Marie Feser3, Fan Zhang4, David Boyle5, Kristine Kuhn4, Kristen Demoruelle6, Cate Speake7, Jane Buckner8, Ananda Goldrath1, Thomas Bumol9, V. Michael Holers10, Peter Skene1, Gary Firestein11, Xiaojun Li1, Kevin Deane12, Troy Torgerson13 and Mark Gillespie1, 1Allen Institute for Immunology, Seattle, WA, 2Allen Institute for Immunology, Seattle, 3Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 4University of Colorado, Aurora, CO, 5UCSD, La Jolla, CA, 6University of Colorado Anschutz Medical Campus, Golden, CO, 7Benaroya Research Institute at Virginia Mason, Seattle, 8Benaroya Research Institute, Seattle, WA, 9Allen Institute for Immunology, San Diego, CA, 10University of Colorado, Denver, CO, 11University of California, San Diego, San Diego, CA, 12University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 13Allen Institute for Immunology, Enumclaw, WA

    Background/Purpose: Multiple T cell subsets, including Th1, Th17 cells, and Tfh/Tph, contribute to rheumatoid arthritis (RA) pathology. Clinical trials have shown efficacy of T cell…
  • Abstract Number: 0933 • ACR Convergence 2024

    NLRP3 Inflammasome Promotes Release of Peptidyl Arginine Deiminases2 and 4 from Human Neutrophils

    Teneema Kuriakose, Mingxin Yang, Lacie Scaletta and Gary Sims, Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD

    Background/Purpose: Autoantibodies targeting citrullinated proteins (ACPAs) are a characteristic feature and a diagnostic marker in rheumatoid arthritis (RA). The generation of citrullinated protein autoantigens is…
  • Abstract Number: 1349 • ACR Convergence 2024

    Two Composite Cytokine Scores Predict Flare and Drug-free Remission in Patients with Rheumatoid Arthritis

    Jasmine Sim1, Nandhini Ramamoorthi2, Fiona Rayner3, Abbie Degnan1, Imogen Wilson1, Julie Diboll1, Anna Guttman4, Andrew Melville5, Nisha Rathore2, Stefan Siebert5, Iain McInnes6, Carl Goodyear5, Catharien Hilkens1, Andrew Filer7, Karim Raza7, Christopher Buckley8, Arthur Pratt1, James Wason9, Amy Anderson1, Michael Townsend2, Kenneth Baker1 and John Isaacs1, 1Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, 2Genentech, South San Francisco, CA, 3Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom, 4Genentech, South San Franscisco, CA, 5School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, 6University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, 7Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, University of Birmingham, Birmingham, United Kingdom, 8Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, 9Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom

    Background/Purpose: Recent studies show that half of patients with RA remission can stop conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) therapy to achieve drug-free remission (DFR),…
  • Abstract Number: 1648 • ACR Convergence 2024

    In Vitro Expansion of ACPA-positive B Cells from Rheumatoid Arthritis Patients and Effect of Small Molecule NF-κB Inhibitors on Differentiation and Survival of (Autoreactive) Memory B Cells into Plasma Cells

    Giulia Frazzei1, Ana Merino Vico2, Jan Piet van Hamburg2, Ronald Van Vollenhoven3 and Sander Tas4, 1Amsterdam University Medical Center, location AMC, Amsterdam, Netherlands, 2Amsterdam UMC, Amsterdam, Netherlands, 3Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands, 4Amsterdam UMC, locatie AMC, Amsterdam, Netherlands

    Background/Purpose: Anti-citrullinated protein antibodies (ACPA) play a role in rheumatoid arthritis (RA) pathogenesis and are associated with disease severity. Detailed analysis of ACPApos B cells…
  • 1
  • 2
  • 3
  • …
  • 7
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology